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Simple Summary: The gap junction protein connexin 43 (Cx43) facilitates direct intercellular
communication and displays a complex dichotomous role in cancer. Here, we used breast cancer cell
lines and CRISPR/Cas9 technology to dissect some of the poorly understood multimodal functions of
Cx43 in this setting. Our data show that Cx43 directly modulates the formation of pro-tumorigenic
tunneling nanotubes (TNTs), which are cellular protrusions that connect non-adjacent cells to facilitate
cellular communication, including the direct cell–cell transfer of organelles. We identify several
important cancer signaling pathways that affect TNT formation and show that this effect is strongly
influenced by the presence or absence of Cx43. Finally, we demonstrate that Cx43 can affect TNT
formation by modulating the cellular secretome. This work provides important insight into the
pro-tumorigenic role of Cx43 and its interconnections with TNTs.
Abstract: Connexin 43 (Cx43) forms gap junctions that mediate the direct intercellular diffusion of
ions and small molecules between adjacent cells. Cx43 displays both pro- and anti-tumorigenic
properties, but the mechanisms underlying these characteristics are not fully understood. Tunneling
nanotubes (TNTs) are long and thin membrane projections that connect cells, facilitating the exchange
of not only small molecules, but also larger proteins, organelles, bacteria, and viruses. Typically,
TNTs exhibit increased formation under conditions of cellular stress and are more prominent in
cancer cells, where they are generally thought to be pro-metastatic and to provide growth and
survival advantages. Cx43 has been described in TNTs, where it is thought to regulate small molecule
diffusion through gap junctions. Here, we developed a high-fidelity CRISPR/Cas9 system to knockout
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(KO) Cx43. We found that the loss of Cx43 expression was associated with significantly reduced
TNT length and number in breast cancer cell lines. Notably, secreted factors present in conditioned
medium stimulated TNTs more potently when derived from Cx43-expressing cells than from KO cells.
Moreover, TNT formation was significantly induced by the inhibition of several key cancer signaling
pathways that both regulate Cx43 and are regulated by Cx43, including RhoA kinase (ROCK), protein
kinase A (PKA), focal adhesion kinase (FAK), and p38. Intriguingly, the drug-induced stimulation
of TNTs was more potent in Cx43 KO cells than in wild-type (WT) cells. In conclusion, this work
describes a novel non-canonical role for Cx43 in regulating TNTs, identifies key cancer signaling
pathways that regulate TNTs in this setting, and provides mechanistic insight into a pro-tumorigenic
role of Cx43 in cancer.
Keywords: connexin 43; gap junctions; cancer; intercellular communication; breast cancer;
cell signaling; tunneling nanotubes; cell–cell communication; tumor microtubes
1. Introduction
Twenty-one human connexin proteins form the main structural units of gap junctions, which are
intercellular channels that allow the direct diffusion of ions and small molecules between neighboring
cells [1]. The critical importance of connexins and gap junctional intercellular communication (GJIC) in
normal tissue physiology is evident from the multitude of human diseases associated with connexin
mutations and the dysregulation of gap junctions observed in many pathological conditions [2].
More than 50 years of research show that GJIC and connexins are implicated in cancer progression and
often act as tumor suppressors [3]. This has led to a significant drive toward the use of connexins as
prognostic markers and therapeutic targets in cancer [4]. Although considered tumor suppressors,
emerging evidence suggests that connexins can promote tumor growth and survival, particularly in
advanced metastatic disease states [3–5].
In addition to facilitating GJIC, connexins are thought to possess channel-independent functions.
Numerous such functions have been described for connexin 43 (Cx43), the most widely expressed and
studied connexin. Notably, many protein–protein interactions in the Cx43 C terminus are thought
to regulate important cancer signaling pathways such as c-Src [6]. Interestingly, Cx43 can take up
residence in unexpected intracellular compartments, including the inner membrane of mitochondria
and the nucleus [7], and Cx43 has been ascribed a functional role in exosomes [8,9]. Furthermore,
we and others have shown that Cx43 produces a single mRNA transcript that is capable of synthesizing
various N-terminally truncated isoforms through a unique mechanism of direct internal translation
initiation [10–12]. The major truncated form, named GJA1-20k, corresponds to the C-terminal tail of
Cx43 and can interact with numerous proteins and regulate malignant features in cancer cells, including
proliferation, migration, and epithelial-to-mesenchymal transition (EMT) [6]. Notably, GJA1-20k
modulates the motility and biogenesis of mitochondria [13,14] and regulates actin dynamics [15].
GJA1-20k has also been described in exosomes [16] and, surprisingly, in the nucleus, where it may act
as a transcriptional regulator of N-cadherin during EMT [17]. These emerging non-canonical functions
of Cx43 are providing new biological insight into cancer, as well as therapeutic opportunities [4,18].
However, dissection of the channel-dependent and -independent functions driving both the anti- and
pro-tumorigenic pathways remains a major challenge.
Tunneling nanotubes (TNTs), first described in 2004 [19], are thin, actin-based, membrane bridges
enclosed in a lipid bilayer that connect cells over distances of up to several cell diameters [20,21]. A wide
variety of TNT-mediated cargo transport has been described, including that of ions [22], miRNAs [23],
cytosolic proteins [24], and prions [25–27], pathogens, such as viruses [28,29] and bacteria [30],
and organelles, such as the endoplasmic reticulum [31], mitochondria [32], Golgi vesicles [31],
endosomes [33], and lysosomes [33]. Due to the heterogeneous nature of these transient structures,
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the terms “thin” and “thick” have been used to differentiate between TNTs with smaller (<0.7 µm)
and larger (>0.7 µm) diameters, respectively [33,34]. “Thin” TNTs contain mainly F-actin, whereas
“thick” TNTs tend to contain both actin and microtubules. TNTs may originate when two joined
cells move apart from each other and remain connected by a thin membranous thread [35] or when
filopodia-like protrusions from one cell dock with a nearby cell [19]. These models are not mutually
exclusive. The underlying molecular mechanisms are not fully understood and likely depend on the
specific cell type and its environment. Indeed, it appears that several types of TNT-like structures exist,
including what are known as tumor microtubes, which are longer and seemingly more stable [36].
A better understanding of the molecular mechanisms underlying the formation and functions of TNTs
is necessary to fully understand their physiological and pathological roles.
Cellular stress, such as hypoxia or a low-serum hyperglycemic medium, seems to stimulate
TNT formation. In particular, TNTs have been described in several cancer cell lines, as well as
between cancer cells and stromal cells (reviewed in [37,38]). TNTs have also been found in primary
human tumors [39–41]. It is becoming clear that TNTs facilitate a pathway of intercellular conduits in
tumors [42] and may promote numerous malignant features such as invasion, growth, chemo- and
radiotherapy resistance, and surgery-induced tumor growth [43–45].
Connexins localize to TNTs and regulate intercellular communication [44,46,47]. Wang et al. [46]
identified TNT-mediated voltage-sensitive electrical coupling that was inhibited by the gap
junction inhibitor meclofenamate. Cx43 immunoreactivity was observed at one end of the TNTs.
Lock et al. [48] showed that TNTs between HeLa cells created cytosolic continuity allowing inositol
triphosphate-mediated calcium signaling, but only if a pair of cells were both expressing Cx43.
More recently, human immunodeficiency virus (HIV) infection was shown to stimulate TNT formation
and connect human macrophages. These TNTs contained Cx43 at the tip, and treatment with the GJIC
inhibitors 18-alpha-glycyrrhetinic acid or octanol prevented TNT-mediated cell–cell communication
and viral cell–cell spread [49]. Although these inhibitors are nonspecific and affect several other
targets and channel proteins, the findings suggest that Cx43 channels may be required for the
functional establishment of TNTs that then allow the transfer of larger structures (including HIV) that,
due to size constraints, do not pass through gap junctions. Notably, recent work suggests that Cx43
regulates TNT formation in normal human trabecular meshwork cells [50]. Yao et al. showed that
Cx43 mediates TNT formation and mitochondrial transfer from human-induced pluripotent stem
cell-derived mesenchymal stem cells and mouse epithelial cells [51]. Mechanistically, Fykerud et al. [52]
showed that Cx43 remodeling was driving the formation of actin-based plasma membrane bridges
(termed “mitotic nanotubes”) with adjacent cells during mitosis, facilitating vesicle transfer between
cells. In vivo, glioma cells have been described to form a network of TNT-like structures called
microtubes that contribute to tumor invasion in the brain [40]. Cx43-containing gap junctions within
this network are thought to turn the tumor into a syncytium of interconnected cells that is highly
resistant to radiation therapy, presumably by distributing calcium between cells to prevent apoptosis
upon the radiation-induced release of intracellular calcium [40]. Brain tumors appear to employ a
similar system of microtubes or TNTs to establish connections with neurons to “feed off the brain” [53].
Similarly, breast cancer cells that metastasize to the brain benefit from the formation of pseudo-tripartite
synapses between cancer cells and glutamatergic neurons to promote metastatic growth [54,55]. Indeed,
several studies have described the presence of TNTs in breast cancer cells and between breast cancer
cells and macrophages, facilitating drug resistance, invasion, and metastasis [56–59]. A large body
of data suggests that Cx43 is intricately linked to breast cancer development and may act as a tumor
suppressor, particularly at early stages (see reviews [60–64]). However, increasing evidence suggests
that some breast cancers overexpress Cx43, which may facilitate certain malignant and metastatic
capabilities. Most notably, the expression of Cx43 was shown to create a syncytium between breast
cancer cells and astrocytes, forming a cyclic guanosine monophosphate–adenosine monophosphate
(cGAMP)-driven paracrine feedback loop that supports tumor growth and chemoresistance [65].
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Consequently, the GJIC inhibitor meclofenamate is under clinical trial for breast cancer patients with
brain metastasis (https://clinicaltrials.gov/ct2/show/NCT02429570).
Considering the emerging evidence linking Cx43 and TNTs, we sought to further explore this
interplay in breast cancer cells by knocking out Cx43 expression using CRISPR-Cas9 technology.
We show that Cx43 significantly regulates the formation and length of TNTs in breast cancer cells.
Notably, TNT stimulation was more potent with conditioned medium derived from Cx43-expressing
cells than with that from Cx43 knockout (KO) cells. Furthermore, several pathways that are regulated
by Cx43 were identified to induce TNTs. Some of these pathways are novel TNT modulators. These
pathways also regulate Cx43 function, and thus the direct association needs to be explored further.
Specifically, Cx43 KO cells were more sensitive to drug-induced TNT formation than wild type (WT)
cells. Further elucidation of the role of Cx43 in this setting is an exciting cutting-edge challenge that
can provide mechanistic insight into the pro-metastatic features of Cx43 and the regulation of TNTs.
2. Results
2.1. GJA1 Knockout Reduces TNT Number and Length in BT549 Breast Cancer Cells
To achieve the full and long-term elimination of Cx43 expression from cells, we developed an
all-in-one transient CRISPR/Cas9 expression plasmid that targets GJA1 (encoding Cx43) and truncated
forms of the protein such as GJA1-20k. The well-established PX458 plasmid allows the expression
of CRISPR targeting sequences together with an EGFP-linked form of Cas9 to control transfection
and fluorescence-activated cell sorting (FACS) selection [66]. To minimize putative off-target cleavage
effects, we replaced the standard Cas9 with the VP12 high-fidelity Cas9 version [67]. Specific sequences
targeting the coding exon of GJA1 were introduced. We transfected various cell lines and used FACS to
isolate single cells transiently expressing Cas9-EGFP. Clones were screened by western blot to detect
loss of Cx43 expression. This tool has allowed us to generate a wide variety of cancer cell lines lacking
Cx43 expression to evaluate various phenotypic changes related to malignancy.
We noticed that the triple-negative breast cancer cell line BT549 tends to display an extensive
TNT network (Figure 1a) that stains for F-actin (Figure 1b). Time-lapse microscopy clearly highlighted
this network and showed that the formation of these TNTs may occur through the protrusion of
filopodia-like structures that connect to a distant cell and/or through two adjacent cells migrating apart
from each other (Supplementary Video S1). We previously showed that this cell line expresses very
high levels of full-length Cx43, as well as the 20-kDa truncated form GJA1-20k [10]. We efficiently
eliminated GJA1 expression from this cell line using our CRISPR-Cas9 plasmid (Figure 1c). This led
to a marked but not complete loss of GJIC, suggesting that other connexin channels may operate in
this cell line (Figure S1). Morphologically, we observed a noticeable reduction in the number of TNTs
in knockout (KO) cells compared with WT cells. Detailed quantification demonstrated that the loss
of Cx43 expression significantly reduced the average numbers of TNTs, both 24 (Figure 1d) and 48
(Figure 1e) h after seeding.
Next, we decided to deliberately stress cells by culturing them in low-serum hyperglycemic media,
which was a condition previously shown to stimulate TNT formation [39]. Using such TNT-inductive
media (im+), the number of TNTs noticeably but nonsignificantly increased (Figure 1f). The difference
between WT and KO cells was significant under im+ conditions (Figure 1f), altogether suggesting that
the response to this specific condition of cellular stress is similar in WT and KO cells. In addition to
having noticeably thicker TNTs, BT549 cells also display some very thin TNTs at 20×magnification
or higher (see white arrow, Figure 1a). After the inclusion of these “thin” TNTs via the analysis of
20× images, the difference between WT and KO cells remained similar and significant (Figure 1g),
together with a significant (and expected) increase in the number of TNTs per cell (Figure 1h). Similar
to our 10× analysis, our 20× analysis suggested that low-serum hyperglycemic conditions stimulated
TNT formation, albeit nonsignificantly (Figure 1i). The results of the detailed 20× analysis seemed to
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strongly correspond with our 10× analysis in terms of differences between cells and were not repeated
for subsequent analyses.
Since there was a significant decrease in the number of TNTs in KO cells, we also compared lengths.
We found a significant reduction in TNT length in the absence of Cx43 (Figure 1j). This was noticeable
but not significant at 48 h, possibly because cells are at a higher density at this stage (Figure 1k).
TNT-inductive medium (im+) also appeared to increase the length of TNTs in both WT and KO cells
(Figure 1l).
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Figure 1. Tunneling nanotubes (TNTs) are regulated by connexin 43 (Cx43) in BT-549 cells.
(a) Morphological examples of TNTs in BT549 cells (20×). The black arrow denotes a typical
“thick” TNT, whereas the white arrow denotes a typical “thin” TNT that is often only visible at
higher magnifications. (b) Confocal image of BT-549 cells stained with F-actin and the nuclear stain
4′,6-diamidino-2-phenylindole (DAPI) demonstrating a long, thin, F-actin–positive TNT. (c) Western
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blot with independently isolated samples of three wild type (WT) and three CRISPR-Cas9 Cx43
knockout (KO) BT549 cells showing the presence or absence (respectively) of both Cx43 (43 kDa) and
the truncated GJA1-20k form (20 kDa), as well as some other weakly expressed truncated forms of
Cx43. The blot was co-incubated with a vinculin antibody (124 kDa) as an internal loading control.
(d,e) Average numbers of TNTs per cell in WT and Cx43 KO BT549 cells at 10× (counting thick TNTs)
(d) 24 h after seeding, (e) 48 h after seeding with cells, and (f) 24 h after seeding followed by 24 h
refreshed with the same medium or in a low-glucose, low-serum inductive medium (im+) to stimulate
TNT formation. (g) Average numbers of TNTs per cell in WT and Cx43-KO BT549 cells at 20× (counting
thick and thin TNTs) 24 h after seeding. (h) Comparison of the numbers of TNTs counted at 10× and
20×. (i) Average numbers of TNTs at 48 h with or without TNT-inductive medium (im+) for the last
24 h. (j–l) Average lengths of TNTs at (j) 24 and (k) 48 h and (l) 48 h with or without treatment with
TNT-inductive medium (im+) for the last 24 h. The means of individual experiments (calculating the
average number of TNTs per cell [TNTs/cell] in n = 5 images) are highlighted and linked by color
and shape to facilitate the tracking of trends between individual experiments. Error bars denote the
mean and SEM of three independent biological experiments. Significance was tested with two-way
Student’s t-test for single comparisons and one-way ANOVA with Tukey’s post-hoc analysis for
multiple comparisons (* p < 0.05, ** p < 0.01, ns = not significant).
2.2. GJA1 Knockout Reduces the Number of TNTs in Hs578t Breast Cancer Cells
To confirm that the Cx43-mediated regulation of TNT formation is a more general phenomenon
and not unique to the BT549 breast cancer cell line, we decided to analyze a second triple-negative
breast cancer cell line that expresses high levels of Cx43. We chose to analyze the Hs578t cell line
because this Cx43-expressing cell line displayed a considerable amount of TNTs under basal conditions
(Figure 2a). Moreover, small interfering RNA-mediated silencing of Cx43 has been shown to affect
malignant features in this cell line [68]. We applied CRISPR/Cas9 to knockout Cx43 (and GJA1-20k)
expression (Figure 2b). This led to a significant reduction in the number of TNTs (Figure 2c). However,
WT Hs578t cells exhibited markedly fewer TNTs compared with BT549 cells (approximately two-fold,
Figure 1d vs. Figure 2c). Other breast cancer cell lines do not have an appreciable amount of TNTs (see
below). Considering that Hs578t cells display an “intermediate” level of TNTs, we considered this
cell line an ideal model to test for any positive or negative effects on TNT formation caused by the
targeting of specific pathways known to be regulated by Cx43.
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Figure 2. TNTs are regulated by Cx43 in HS578t cells. (a) Morphological examples of TNTs in HS578t
cells (20×). The white arrow denotes a typical TNT. (b) Western blot of WT and CRISPR-Cas9 Cx43KO
Hs578t cells showing the presence or absence of Cx43 (43 kDa) and the truncated GJA1-20k form
(20 kDa). Vinculin (124 kDa) was used as a loading control. (c) Average numbers of TNTs per cell
in WT and Cx43-KO Hs578t cells at 10× (counting thick TNTs) 24 h after seeding. The means of
individual experiments (calculating the average number of TNTs per cell [TNTs/cell] in n = 5 images)
are highlighted and linked by c lor and shape to facilita e the tracki g of trends betwe n individual
experiments. Error bars denote the mean an SEM of three independent biological experiments.
Significance was tested using the two-way Student’s t-test (** p < 0.01, ns = not significant).
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2.3. Signaling Pathways Linked to Cx43 Differentially Affect TNT Formation in Cx43 WT and KO Cells
TNT formation is closely linked to the cytoskeletal network, with disruption of F-actin
polymerization reducing TNT formation [69]. Rho-GTPases regulate actin polymerization, such
as during the formation of TNTs [70]. RhoA signaling, including Rho-associated protein kinase (ROCK),
is regulated by Cx43 in breast epithelial cells [71], which is an observation supported by us in Hs578t
cells (Figure S2). RhoA signaling can also affect Cx43 expression levels and channel activity [72–74].
Thus, we decided to inhibit actin stress fiber formation with the ROCK inhibitor Y-27632. In this
case, we observed a highly significant increase in the number of TNTs (as illustrated in Figure 3a–d
and summarized in Figure 3e). This is consistent with results published for other cell types [69].
Curiously, this effect was even stronger in KO cells (mean increase of 0.97 TNTs/cell vs. a mean
increase of 0.61 TNTs/cell in WT cells). This observation reinforces the idea that the effect of Y-27632 is
exerted on RhoA signaling and not on any Cx43-related mechanisms. In support of a RhoA-associated
mechanism, we observed a trend toward a reduced F-/G-actin ratio in KO cells compared with WT
cells (Figure S2). As a control for the critical role of F-actin in TNT formation, we applied the actin
polymerization inhibitor latrunculin A, which prevents the assembly of F-actin into supramolecular
structures. As expected, this reduced the number of TNTs in Hs578t cells, especially in WT cells, which
initially contained more TNTs (Figure 3f).
RhoA-ROCK activates p38 [75], another signaling pathway that is regulated by Cx43 [76] and that
regulates Cx43 [6]. We blocked p38 kinase activity using the well-known specific inhibitor SB-203580,
which led to a significant increase in the number of TNTs (Figure 3g). Again, an even higher increase
was observed in KO cells than in WT cells. This is the first report directly showing that the inhibition of
p38 activity can be a potent inducer of TNTs. It is worth noting that Cx43 (or the truncated C-terminal
tail of Cx43) activates p38 to induce the formation of filopodia through upstream interaction with and
activation of p21-activated protein kinase 1 (PAK1) [76]. The inhibition of both p38 and PAK1 reduces
filopodia formation [76]. We also tested the PAK1 inhibitor IPA3 but did not observe any significant
changes in WT or KO cells (Figure 3h). However, IPA3 does not efficiently inhibit PAK2, which is a
kinase that affects RhoA signaling [77]. The fact that both Cx43 and p38 signaling affect TNT (this
study) and filopodia [76] formation in an opposite manner indicates that subtle mechanistic differences
are important and is in accordance with reports that the formation of TNTs and filopodia are driven by
distinct opposing actions of the actin regulatory complexes [78].
Another signaling pathway that regulates the actin cytoskeleton and F-actin dynamics is the cyclic
AMP-dependent protein kinase (cAMP/PKA) pathway [79,80]. PKA also potently regulates Cx43 gap
junctions [81], which are the same gap junctions that are a major conduit for cAMP transfer between
cells. The activation of cAMP/PKA signaling, using either forskolin or the cAMP analog 8-Br-cAMP,
can restore Cx43 gap junctional activity [82]. Notably, activation of PKA by forskolin or 8-Br-cAMP
inhibits downstream RhoA-ROCK signaling [83]. In Hs578t cells, treatment with both 8-Br-cAMP
(Figure 3i) and forskolin (Figure 3j) significantly induced TNT formation in WT cells, and even more so
in KO cells (forskolin reached high significance in a comparison between stimulated WT and KO cells).
We also inhibited PKA activity using the drug H89. Surprisingly, this also potently stimulated TNT
formation (Figure 3k). However, H89 also specifically inhibits downstream RhoA-ROCK signaling,
and H89 might not be suitable as an antagonist of PKA in systems in which ROCK signaling is
important [84].
The extracellular signal-regulated kinase (ERK)/RhoA/focal adhesion kinase (FAK) network
also regulates the cytoskeletal network. FAK interacts with c-Src to mediate many downstream
signaling pathways, including RhoA signaling [85]. Indeed, β1 integrin-mediated modulation of
a FAK–RhoA–actomyosin signaling axis regulates membrane protrusions [86]. Notably, Cx43 is
phosphorylated by Src and, conversely, a region of the Cx43 C terminus also regulates c-Src activity
and Src/FAK signaling [87]. Therefore, we treated cells with the FAK inhibitor PF 431396. This inhibitor
significantly increased TNT numbers in both WT and KO cells (Figure 3l). We also tested a short
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inhibitory peptide known to inhibit FAK/Src activity [87] but did not observe any major difference
(Figure S3).
Cancers 2020, 12, x 8 of 24 
 
 
Figure 3. Drug-induced TNT formation in Hs578t cells upon overnight (16-h) stimulation. (a–d) 
Examples of morphology and TNTs in WT and KO Hs578t cells stimulated overnight with DMSO 
control or the RhoA kinase (ROCK) inhibitor Y-27632, which significantly increased the number of 
TNTs. (e–l) Quantification of the average numbers of TNTs in WT and KO Hs578t cells in DMSO 
control (−) and drug-stimulated (+) cells, as specified in each graph. The means of individual 
experiments (calculating the average number of TNTs per cell [TNTs/cell] in n = 5 images) are 
highlighted and linked by color and shape to facilitate the tracking of trends between individual 
experiments. Error bars denote the mean and SEM of three independent biological experiments. 
Significance was tested using one-way ANOVA with Tukey’s post-hoc analysis for multiple 
comparisons (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, ns = not significant). 
2.4. Drug-Induced Stimulation of TNTs in the Presence or Absence of Cx43 in Cell Lines Expressing Very 
High or Very Low Numbers of TNTs under Normal Conditions 
Since Y-276332 (ROCK inhibitor) and H89 were exceptionally potent at stimulating TNT 
formation, we decided to test these agents in the breast cancer cell line SUM159PT, which displays 
Figure 3. Drug-induced TNT formation in Hs578t cells upon overnight (16-h) stimulation.
(a–d) Examples of morphology and TNTs in WT and KO Hs578t cells stimulated overnight with
DMSO control or the RhoA kinase (ROCK) inhibitor Y-27632, which significantly increased the
number of TNTs. (e–l) Quantification of the average numbers of TNTs in WT and KO Hs578t cells in
DMSO control (−) and drug-stimulated (+) cells, as specified in each graph. The means of individual
experiments (calculating the average number of TNTs per cell [TNTs/cell] in n = 5 images) are highlighted
and linked by color and shape to facilitate the tracking of trends between individual experiments.
Error bars denote the mean and SEM of three independent biological experiments. Significance was
tested using one-way ANOVA with Tukey’s post-hoc analysis for multiple comparisons (* p < 0.05,
** p < 0.01, *** p < 0.001, **** p < 0.0001, ns = not significant).
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2.4. Drug-Induced Stimulation of TNTs in the Presence or Absence of Cx43 in Cell Lines Expressing Very High
or Very Low Numbers of TNTs under Normal Conditions
Since Y-276332 (ROCK inhibitor) and H89 were exceptionally potent at stimulating TNT formation,
we decided to test these agents in the breast cancer cell line SUM159PT, which displays very few TNTs
under basal conditions, despite expressing some Cx43 (but low levels of GJA1-20k). We also generated
a Cx43 KO version of this cell line (Figure 4a). Both Y-276332 (Figure 4b) and H89 (Figure 4c) stimulated
the de novo formation of TNTs in both WT and KO cells, although the results were only significant in
KO cells. Indeed, TNT induction was significantly more potent in KO cells (16.8-fold and 4.3-fold more
potent stimulation in KO cells than in WT for ROCK and H89, respectively). We also confirmed that
these inhibitors potently stimulated TNT formation in the BT549 cell line, which already expresses
a very high number of TNTs (Figure 4d,e). In this instance, overall TNT induction was slightly less
potent in KO cells than in WT cells (although the ratio increase was still higher). A complex interplay
between Cx43-related pathways is involved in TNT formation.
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GJIC inhibitors such as meclofenamate and 18-alpha-glycyrrhetinic acid affect TNT-mediated 
cell coupling without affecting TNT formation because their activity is reversible upon drug washout 
[46,49]. We tested the GJIC inhibitor meclofenamate in Hs578t cells because these cells mainly express 
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Figure 4. Drug-induced TNT formation in SUM159PT and BT549 cells. (a) Western blot of WT and
CRISPR-Cas9 Cx43 KO cells showing the presence or absence of Cx43 (43 kDa) in SUM159PT cells.
Vinculin (124 kDa) was used as a loading control. (b,c) Average numbers of TNTs per cell in WT
and Cx43 KO SUM159PT cells with or without the inhibitors Y-27632 (b) and H89 (c). (d,e) Average
numbers of TNTs per cell in WT and Cx43-KO BT549 cells with or without the inhibitors Y-27632
(d) and H89 (e). The means of individual experiments (calculating the average number of TNTs per cell
[TNTs/cell] in n = 5 images) are highlighted and linked by color and shape to facilitate the tracking
of trends between individual experiments. Error bars denote the mean and SEM of two independent
biological experiments. Significance was tested using one-way ANOVA with Tukey’s post-hoc analysis
for multiple comparisons (* p < 0.05, ** p < 0.01, *** p < 0.001, ns = not significant).
2.5. Further Insight into Cx43 Pathways Stimulating TNT Formation
Our results show that Cx43 stimulates TNT formation in breast cancer cells. Furthermore,
the inhibition of several pathways linked to Cx43, such as p38 and ROCK, appears to stimulate
TNT formation more effectively in KO cells. We adopted several experimental approaches to obtain
additional insight into the molecular pathways through which Cx43 may affect TNTs.
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2.5.1. The role of GJIC
GJIC inhibitors such as meclofenamate and 18-alpha-glycyrrhetinic acid affect TNT-mediated cell
coupling without affecting TNT formation because their activity is reversible upon drug washout [46,49].
We tested the GJIC inhibitor meclofenamate in Hs578t cells because these cells mainly express Cx43 and
because KO cells are almost devoid of GJIC (Figure S4). Meclofenamate specifically reduced the levels
of TNTs in WT cells and not in KO cells, albeit nonsignificantly (Figure 5a). However, flow cytometry
analysis of the parachute dye-transfer assay suggested a very modest inhibition of GJIC (Figure S4).
Another GJIC inhibitor, carbenoxolone (CBX), a glycyrrhetinic acid derivative (that notably also affects
Cx43 levels and inhibits pannexin1 channels), also seemed to specifically reduce TNT levels in WT
cells (Figure 5b). Cx43 KO cell lines provides an important tool in this setting to compare GJIC-specific
and -unspecific effects (Figure 1c, Figure 2b, Figure 4c and Figure S5). However, due to the nonspecific
and potentially toxic effects of these inhibitors and considering the sensitivity of TNTs to injury, for
example, additional experiments are required to conclude whether GJIC directly affects TNT formation
or only TNT function. Toward this, a preliminary peptide screen indicated that the channel- and
hemichannel-inhibiting Cx43 mimetic peptide Gap27 does not seem to have a major effect on TNT
levels (Figure S3).
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conditioned medium to induce TNTs. As seen in Figure 6, conditioned medium stimulated TNT 
formation. Notably, medium from WT cells was significantly more potent than medium from KO 
cells, suggesting that the presence of Cx43 at least partly stimulates TNT formation by modifying the 
secretome. Since Cx43 is present in numerous cell types, it will be of particular interest to elucidate 
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Figure 5. Stimulation of TNT formation through gap junctional intercellular co unication ( JI )
and GJA1-20k. (a) Inhibition of GJIC by meclofenamate. (b) Inhibition of JI by carbenoxolone
(CBX). (c) Overexpression of Cx43 and GJA1-20k in Hs579t Cx43 KO cells. The eans of individual
experiments (calculating the average number of TNTs per cell [TNTs/cell] in n = 5 images) are highlighted
and linked by color and shape to facilitate the tracking of trends between individual experiments.
Error bars denote the mean and SEM of three or more independent biological experiments as indicated.
Significance was tested using one-way ANOVA with Tukey’s post-hoc analysis for multiple comparisons
(ns = not significant).
2.5.2. Channel-I dependent Effects
On the other hand, regulation of he cytoskeleton (cr tical for TNT formation) is thought to be
mediated by on-junctional features of the Cx43 C terminus [6,88]. For exampl , the ov rexpression
of the Cx43 C terminus regulates filopodia formation [76], and the independently translated Cx43
C-terminal prot in GJA1-20k r gulates actin dynamics [15]. Therefore, w overexpressed either
GJA1-20k or Cx43 in Hs578t Cx43KO cells and quantified the levels of TNTs. Increased TNT for ation
was ob erved (Fi ure 5c), but the ffect was relatively weak and did not reach statistical significanc ,
ev n in control Cx43-overexpr ssing cells. Additional approaches, including over xpression in th
absence of EGFP, are needed to draw fir r conclusions.
2.5.3. Induction of TNTs by Conditioned Media
Previous work has shown that conditioned medium from macrophages stimulates TNT formation
in breast cancer cells [57,59]. Cx43 significantly alters the secretome and affects features such as the
Cancers 2020, 12, 2798 11 of 25
actin cytoskeleton [89]. Therefore, we tested whether Cx43 affected the ability of conditioned medium
to induce TNTs. As seen in Figure 6, conditioned medium stimulated TNT formation. Notably, medium
from WT cells was significantly more potent than medium from KO cells, suggesting that the presence
of Cx43 at least partly stimulates TNT formation by modifying the secretome. Since Cx43 is present
in numerous cell types, it will be of particular interest to elucidate the mechanism of Cx43-driven
secretome-mediated TNT stimulation.Cancers 2020, 12, x 11 of 24 
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of TNTs per cell in WT and Cx43 KO Hs578t cells. C = control conditions. +KO = stimulation with
conditioned medium derived from Hs578t Cx43 KO cells. +WT = stimulation with conditioned medium
derived from Hs578t WT cells expressing Cx43. The means of individual experiments (calculating
the average number of TNTs per cell (TNTs/cell) in n = 5 images) are highlighted and linked by color
and shape to facilitate the tracking of trends between individual experiments. Error bars denote the
mean and SEM of three or more independent biological experiments, as indicated. Significance was
tested using one-way ANOVA with Tukey’s post-hoc analysis for multiple comparisons (* p < 0.05,
**** p < 0.0001, ns = not significant).
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inter-relationship between these signaling pathways and Cx43 appears to exist (Figure 7), although the
main driving force for TNT formation in this setting remains to be defined.
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The stimulation of TNTs upon ROCK inhibition was even more potent in Cx43 KO cells. This was
a surprising observation that also was seen upon the inhibition of p38. These pathways are closely
linked. RhoA–ROCK activates p38 [75] and activation of RhoA induces p38-dependent pseudopodial
protrusions [100]. We used multiple breast cancer cell lines to show for the first time that p38 is a direct
regulator of TNT formation. However, indirect targeting of p38, by blocking its upstream activator
PAK1 with the drug IPA-3, inhibits TNT formation in a neuroblastoma cell line [101]. Moreover,
the truncated form of Cx43 stimulates filopodia formation by activating p38 through phosphorylation
of the upstream target PAK1, with filopodia formation significantly reduced via IPA-3 inhibition of
PAK1 activity [76]. However, the formation of filopodia and TNTs is stimulated through opposing
pathways of the actin regulatory network, and the filopodia-promoting CDC42/IRSp53/VASP network
negatively regulates TNT formation [78]. Our results are in agreement with this observation, with Cx43
KO cells forming significantly more TNTs in response to p38 inhibition compared with Cx43-expressing
cells, which explains why p38 inhibition may reduce filopodia formation but induce TNTs in breast
cancer cell lines. The role of PAK1 in this setting remains unclear, because IPA-3 did not significantly
affect TNT levels.
p38 induces stress fiber formation, which can be blocked by p38 inhibition [102,103]. RhoA and
FAK are also critical regulators of actin stress fibers [104]. Moreover, the improper alignment
of actin stress fibers is observed in migrating fibroblasts derived from Cx43 KO mice [105].
Cx43 also inhibits FAK signaling and—perhaps not surprisingly considering the close links between
FAK/RhoA/p38-signaling—the inhibition of FAK signaling increases TNT levels. However, this finding
does contrast with that of a study showing that FAK inhibition can reduce TNT levels in squamous
cell carcinoma cells [106]. The frequent observation of the cell line-dependent regulation of TNTs
further cements the idea that TNT formation is a highly complex process involving various cell
context-dependent pathways.
A clear observation from the kinase inhibition experiments was that although WT cells had more
TNTs under basal conditions, KO cells responded more potently to the drugs and induced higher
levels of TNTs than WT cells. The underlying reason is not clear, but one can speculate that under
basal conditions, Cx43 promotes the formation of TNTs (to maintain contact and synchrony in the
cell population), whereas, upon stress, Cx43 can hinder the formation of new TNTs (to avoid the
dissemination of negative signals and circumvent the damage). Indeed, these “kiss of life” and “kiss of
death” phenomena are well-described for classic gap junctions mediating the bystander effect between
adjacent cells, such as in cancer progression and the therapeutic response [4,107]. The molecular
mechanism controlling this aspect remains unclear, but a balance between multiple cell signaling
pathways likely controls the overall fate of the cell in terms of TNT establishment.
It remains unclear whether channel-dependent or -independent mechanisms are the dominant
Cx43-mediated pathways influencing TNTs. From the literature, multiple hypotheses can be postulated,
including a role for the independently synthesized truncated forms of Cx43 in directly regulating
the intracellular signaling pathways affecting TNTs. Our study supports this hypothesis. GJA1-20k
arranges actin (maintaining F-actin structure) to guide Cx43 delivery [15], as well as potentially that of
other proteins involved in membrane dynamics. The Cx43/ZO-1 complex also regulates endothelial
F-actin architecture [108]. Additionally, GJA1-20k contains a microtubule-binding motif that promotes
microtubule polymerization [11,105,109,110]. Expression of the truncated Cx43 form GJA1-20k did
seem to induce TNTs in our KO cells, although additional experiments are needed to dissect the
molecular pathway and draw firm conclusions.
Apart from regulating the function of TNTs, GJIC may also regulate their formation. Indeed,
the inhibition of GJIC using chemical inhibitors suggested that fewer TNTs were formed, specifically
in WT and not KO cells. However, these chemical inhibitors affect a number of other pathways that
may influence TNTs, and our preliminary experiments using a more specific peptide-based approach
to inhibit Cx43 channels did not prove fruitful. This issue might be deciphered by the use of other
connexin species to restore GJIC. Moreover, it should be noted that the formation of TNTs seems
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highly sensitive to cellular conditions, including time in tissue culture, seeding density, and duration
of trypsinization and other factors that affect cell health. This variation can be appreciated in our study,
because individual biological replicates have been color-/shape-coded to allow the tracing of trends
between replicates and experiments performed on different days. Such variation reduces the statistical
significance and reinforces the importance of maintaining the cellular conditions as similar as possible.
We also noted significant variation among cell lines. BT549 and Hs578t are triple-negative breast
cancer cells (with a mesenchymal phenotype) [111] that display particularly high levels of TNTs. Other
triple-negative cell lines, such as SUM159PT (as shown here) and MDA-MB-231, as well as estrogen
receptor-positive MCF-7 cells, also express TNTs, but to a lesser extent [58,59,112–114]. In this context,
comparative gene expression analysis of both WT and Cx43 KO cells may provide valuable insight
into the regulatory pathways important for TNT formation.
Finally, Cx43 affects the secretome [89], and our results clearly show that conditioned medium from
Cx43 WT cells was a significantly more potent inducer of TNTs than that from KO cells. This suggests
that Cx43 can affect TNTs in more distant cells as well as potentially in other cell types. This will be
an exciting avenue to explore in the future. Notably, exosomes have been shown to stimulate TNT
formation [115]. The silencing of RASSF1A inactivates the RhoB guanine nucleotide exchange factor
GEF-H1, leading to Rab11 accumulation and subsequent exosome release, which in turn contribute to
TNT formation [116]. An interaction between Cx43 and Rab11 has been described in endocytosis [117],
and vesicles containing Rab11 and Cx43 are transported between mitotic cells and adjacent cells via
actin-based plasma membrane bridges [52]. A Rab11a–Rab8a cascade has been shown to regulate TNT
formation through vesicle recycling [118]. Cx43 is a functional constituent of exosomes [8,9], and Cx43
phosphorylation may promote exosome release [119]. The link between Cx43, exosomes, and TNTs
warrants further investigation.
In conclusion, this work highlights a direct link between Cx43, TNTs, and cell signaling pathways
that may play an important role in cancer progression and provides clues as to why Cx43 is often found
to be pro-tumorigenic in highly malignant and metastatic cancers [4]. Nonetheless, Cx43 is implicated
in many other diseases [2]. Notably, Cx43 plays a central role in ischaemic heart disease, which is a
condition recently described to impact TNT-mediated communication among cardiac cells [120]. Thus,
elucidation of the Cx43–TNT cell communication axis is an important future endeavor with potential
therapeutic opportunities.
4. Materials and Methods
4.1. Cx43 Knockout and Overexpression of Cx43 and GJA1-20k
4.1.1. Generation of an All-in-One High-Fidelity Cbh-hfCas9-2A-eGFP CRISPR Plasmid
pSpCas9(BB)-2A-GFP (PX458), a gift from Feng Zhang (Addgene plasmid #48138; http://n2t.net/
addgene:48138; RRID:Addgene_48138), allows the expression of CRISPR targeting sequences together
with an EGFP-linked form of Cas9 to control transfection and FACS selection [66]. To minimize
putative off-target cleavage, we replaced Cas9 with a high-fidelity Cas9 gene [67] amplified from the
V-T7-humanSpCas9-HF1-NLS-3xFLAG (VP12) vector gifted by Keith Joung (Addgene plasmid #72247;
http://n2t.net/addgene:72247; RRID:Addgene_72247). The hSpCas9 gene was removed by digesting
the PX458 plasmid with FastDigest AgeI (Thermo Scientific; #ER1461, Waltham, MA, USA) and FseI
(New England BioLabs; #R0588S, Hitchin, UK) in CutSmart® Buffer (New England Laboratories;
#B7204S): the AgeI cut site is 1238 bp before the FLAG tag, whereas the FseI cut site is 5499 bp after
the 2A-EGFP sequence. Primers (with AgeI and FseI restriction sites) were designed to amplify by
conventional PCR the SpCas9 hf1 gene and also the T7, SV40 NLS, and FLAG tag sequences (Fw:
5′-GCACCGGTCG GCCGCTAATA CGACTCACTA TAG-3′; Rev: 5′-CTAGGCCGGC CAATCCTGCA
GCCTTGTCAT CGTCATC-3′). The reverse primer was designed to remove the stop codon to allow
continuous in-frame translation of the self-cleaving EGFP present in the receptor vector. We used
Phusion Hot Start High-Fidelity DNA Polymerase (2 U/µL) (New England Laboratories; #M0530L)
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under the recommended conditions and with the following PCR protocol: an activation step (98 ◦C for
30 s), followed by 30 cycles of denaturation (98 ◦C for 10 s), annealing (54 ◦C for 30 s), and elongation
(72 ◦C for 65 s), with a final elongation step (72 ◦C for 10 min). PCR amplification products were
digested with FseI and AgeI and ligated into the digested PX458 using the T4 DNA Ligase System
(Thermo Scientific). The new plasmid, named Cbh-hfCas9-2A-eGFP, was initially screened by KpnI
and SalI double digestion, and the final plasmid was sequenced using the T7 promoter primer
(5′-TAATACGACT CACTATAGGG-3′) and a reverse EGFP N-terminal primer (5′-CGTCGCCGTC
CAGCTCGACC AG-3′).
4.1.2. Cbh-hfCas9-2A-eGFP CRISPR System Targeting Cx43
The gap junction protein alpha 1 (GJA1) gene sequence, encoding the Cx43 protein, was imported
from the Ensembl Database (ENSG00000152661, GRCh38 (hg38, Homo sapiens)). Single small guide
RNAs (sgRNAs) targeting the protein-encoding exon 2 region were designed using the publicly
available tool Benchling (https://benchling.com), which predicts the 5′-NGG-3′ protospacer adjacent
motifs (PAMs) in a given sequence and the potential sgRNAs in both strands, giving their on-target
and off-target scores. We choose 20-nucleotide-long sgRNAs with acceptable on-target and off-target
scores, ensuring that the guides did not contain a BbsI restriction site. The sequences were as follows:
Pair 1, 5′-CACCGAAGCC TACTCAACTG CTGG-3′/5′-AAACTCCAGC AGTTGAGTAG GCTTC-3′;
Pair 2, 5′-CACCGACAGC GGTTGAGTCA GCCTG-3′/5′-AAACCAGGCT GACTCAACCG CTGTC-3′.
The sgRNA oligo duplex was generated using 0.5 µL of T4 Polynuclease Kinase (10 U/µL) (Thermo
Scientific; #EK0031), 1 µL of 10× T4 Ligase Buffer (Thermo Scientific; #B69), 10 µM of forward sgRNA
oligo, 10 µM of reverse sgRNA oligo, and 6.5 µL of nuclease-free water. Phosphorylation and annealing
involved an initial step of 30 min at 37 ◦C, followed by 5 min at 95 ◦C and a 5 ◦C/min decrease
until 25 ◦C. For cloning, the Cbh-hfCas9-2A-eGFP vector was digested with BbsI, which generated
compatible ends with the BbsI-specific overhangs of the sgRNA oligo duplex. The reaction comprised
100 ng of Cbh-hfCas9-2A-eGFP, 1 µL of BbsI (10 U/µL) (Thermo Scientific; #ER1011), 0.5 µL of T4
Ligase (1 U/µL) (Invitrogen, Thermo Scientific; #15224090), 2 µL of 10× Tango Buffer (Thermo Scientific;
#BY5), 0.1 µM of the annealed and phosphorylated sgRNA oligo duplex, 0.5 mM of dithiothreitol
(DTT) and ATP, and nuclease-free water to a total volume of 20 µL. Six 10-min cycles (5 min at 37 ◦C,
then 5 min at 21 ◦C) were followed by a 10-min heat-inactivation step at 65 ◦C. DH5α E. coli cells were
transformed with standard procedures, and plasmid isolation was performed using the commercial
GeneJET Plasmid Miniprep kit (Thermo Scientific; #K0502). Colonies were screened with SalI + BbsI
double digest, and positive clones were verified by sequencing from the U6 promoter (5′-ACTATCATAT
GCTTACCGTA AC-3′).
4.1.3. Generation of KO Clones
Cells were transfected with Lipofectamine 3000 (Thermo Scientific; #L3000015) following the
manufacturer’s instructions. Seventy-two hours later, the cells were sorted (BD FACSAria II cell sorter
(BD Biosciences, San Jose, CA, USA)) and seeded at 1 cell/well in 96-well plates previously prepared
with 150 µL of conditioned medium per well (50% normal medium + 50% conditioned medium).
Clones were screened for Cx43 expression by western blot and immunofluorescence imaging.
4.1.4. Overexpression of Cx43 and GJA1-20k
Cx43-IRES-GFP in the retroviral pLPCX vector (Clontech, Mountain View, CA, USA) has
been previously described [10] and is available as Addgene plasmid #65433. GJA1-20k was
cloned from pDEST-EGFP-Cx43-ML-N1 (Addgene plasmid #49860; http://n2t.net/addgene:49860;
RRID:Addgene_49860) as a template into pEGFP-N2 (Clontech) plasmid by PCR cloning (FW-XhoI:
5′-GCGCTCGAGA TGCTGGTGGT GTCCTTGGTG TCC-3′; and Rv-HindIII: 5′-GCGAAGCTTC
TAGATCTCCA GGTCATCAGG CCG-3′) and digested with XhoI and NotI into the pLPCX vector
and verified by sequencing. Transfection, viral collection, and infection were performed as previously
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described [121]. Cells were sorted by flow cytometry (High Speed Cell Sorter FacsAria (Becton
Dickinson, Franklin Lakes, NJ, USA)) to obtain a population entirely comprising EGFP-positive cells.
4.2. Cell Culture
Human cancer cells Hs578t, BT-549, and SUM159PT (American Type Culture Collection) were
grown in standard Dulbecco’s modified Eagle’s medium (DMEM) (Thermo Scientific) supplemented
with 10% (v/v) heat-inactivated fetal bovine serum (FBS) (Labclinics, Barcelona, Spain) and penicillin
(100 U/mL)–streptomycin (100 U/mL) (Thermo Fisher Scientific) in a humidified incubator (37.0 ◦C,
5% CO2). Hs578t cells were additionally supplemented with human insulin (10 µg/mL) (Sigma-Aldrich,
Deisenhoffen, Germany) to support growth.
4.3. TNT Analysis
Cells (75,000) were seeded into 6-well plates. Unless otherwise stated, the medium was
replaced the following day with either normal DMEM medium, low-serum DMEM (1% FBS),
or drug-/peptide-supplemented DMEM. Then, after overnight incubation, images were taken with a
Nikon Eclipse TE2000-S inverted microscope at 10× magnification. Between 5 and 10 images were
obtained for each condition in each independent experiment, and the numbers of cells and TNTs were
counted to calculate the ratio of TNTs/cell.
4.4. Drug Treatments
Hs578t WT and KO cells (75,000 cells/well) were seeded in a 6-well plate. Drugs were applied and
the cells were incubated overnight (16 h) or for 8 h (for carbenoxolone, PF 431396, IPA-3, and latrunculin
A). The final concentrations of the drugs were as follows: meclofenamate sodium (Chem Cruz;
#sc200532A) 25 µM; forskolin (Sigma-Aldrich; #F6886), 30 µM; latrunculin A (Tocris; #3973, Bristol, UK),
10 nM; SB203580 (Selleckchem; #S1076, Houston, TX, USA), 25 µM; carbenoxolone (Sigma-Aldrich;
#C4790), 25 µM; Y-27632 (Selleckchem; #S1049), 10 µM; IPA-3 (Selleckchem; #S7093), 2.5 µM; 8-Br-cAMP
(Abcam; #ab141448, Cambridge, UK), 100 µM; H89 dihydrochloride (Sigma-Aldrich; #C4790), 20 µM;
and PF 431396 (Tocris; #4278), 5 µM.
4.5. Peptide Treatments
All peptides were custom-synthesized by GeneScript to a minimum purity of 85% and shipped
as a lyophilized powder. The peptides were resuspended in sterile 1× phosphate-buffered saline
(PBS) or dimethyl sulfoxide (DMSO) and added to media at 25 µmol/L. The cells were incubated
overnight. The next morning, 10 random photomicrographs were taken, and the TNT/cell ratio was
calculated. All peptides were screened twice, with the exception of Tat-Cx43 (amino acids 266–283),
for which four independent experiments were performed. The following peptides were tested:
TAT-Cx43(266–283), YGRKKRRQRR RAYFNGCSSP TAPLSPMSP; TAT-Cx43(274–291), YGRKKRRQRR
RPTAPLSPMS PPGYKLVTG; TAT-Cx43(266–283REV), YGRKKRRQRR RAPSMPSLPA TPSSCGY; ACT1
RQPKIWFPNR RKPWKKRPRP DDLEI; ACT1R, RQPKIWFPNR RKPWKKIELD DPRPR; Peptide5,
VDCFLSRPTK T; CT10, SRPRPDEI; Gap27, SRPTEKTIII; and Gap27rev, IIFITKETPS.
4.6. Conditioned Medium Treatment
WT or KO Hs578t cells (500,000 cells) were seeded in 100-mm cell culture dishes and cultured
for 4 days. Conditioned media were collected and filtered through a 0.2-µm filter to ensure sterility.
Three wells of WT cells and three of KO cells were seeded in a 6-well plate at 75,000 cells/well. The cells
were allowed to grow for 24 h. Afterward, the media was aspirated, the wells washed with 2 mL of
1× PBS, and the medium of each well replaced with complete DMEM (control), conditioned medium
from WT cells (CM-WT), or conditioned medium from KO cells (CM-KO). The cells were incubated
overnight before the TNT numbers were quantified.
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4.7. Protein Extraction and Quantification
Cells were lysed with radioimmunoprecipitation assay (RIPA) Lysis Buffer (50 mM Tris-HCl, pH 7.4,
150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM ethylenediaminetetraacetic
acid (EDTA)) (Santa Cruz Biotechnology, Dallas, TX, USA) supplemented with PhosSTOP and Complete
Phosphatase/Protease Inhibitor Cocktails (Roche Diagnostics GmbH, Mannheim, Germany). Protein
was quantified using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific).
4.8. Western Blotting
Complete protein extracts (30 µg) were loaded onto SDS-PAGE gels and electrophoretically
transferred to polyvinylidene fluoride (PVDF) membranes (Thermo Fisher Scientific). Then,
the membranes were blocked with either 5% (w/v) non-fat dry milk or 5% (w/v) bovine serum albumin
(BSA) (Sigma-Aldrich) in phosphate-buffered saline buffer containing 0.1% Tween-20 (Sigma-Aldrich)
and incubated with primary antibody overnight at 4 ◦C. horseradish peroxidase (HRP)-conjugated
secondary antibody incubation was performed at room temperature for 1 h. Protein immunodetection
was performed using ECL™Western Blotting Detection Reagents (GE Healthcare, Buckinghamshire,
UK). The following primary antibodies were used: Cx43 (Sigma-Aldrich; #C6219; 1:8000), vinculin
(Sigma-Aldrich; #V4505; 1:1000), ROCK1 (Santa Cruz Biotechnologies,; #sc-17794; 1:100), ezrin (Santa
Cruz Biotechnologies; #sc-5875; 1:1000), vimentin (Santa Cruz Biotechnologies; #sc-6260; 1:1000), and
RhoA (Cytoskeleton Inc., Denver, CO, USA; #ARH03; 1:1000). The secondary antibodies were rabbit
anti-mouse horseradish peroxidase and goat anti-rabbit horseradish peroxidase (Life Technologies,
Carlsbad, CA, USA; 1:10,000).
4.9. Immunofluorescence Microscopy
Cells were seeded on sterile glass coverslips (20,000 cells/coverslip) and grown to semi-confluency.
After 28–48 h, they were washed once with 1× PBS and fixed with 4% formaldehyde for 15 min at room
temperature. After two additional washes, the cells were permeabilized and blocked in PBS containing
20% goat serum and 0.5% Triton X-100 for 1 h at room temperature (RT). Afterward, the cells were
stained with the ActinRed™ 555 ReadyProbes® Reagent (Thermo Fisher Scientific; #R37112), following
the steps given by the manufacturer. From this step onward, we protected the dish from direct light.
Then, the cells were incubated for 1 h at room temperature with a rabbit anti-Cx43 antibody (Sigma;
#C6219) diluted 1:500 in antibody buffer (1× PBS containing 5% goat serum). Cells were washed
three times with 1× PBS and incubated for 1 h at room temperature with secondary antibody (Alexa
Fluor® 488 goat anti-rabbit [Sigma-Aldrich] diluted at 1:1000 in antibody buffer). Then, the cells were
washed three times with PBS and mounted by placing the coverslips cell-side down on glass slides
with a drop of ProLong Diamond Antifade Mountant containing DAPI (Life Technologies; #P36962) to
automatically stain the nuclei. Samples were stored at 4 ◦C in the dark until analysis. Finally, samples
were observed using an Olympus FSX100 fluorescent microscope or confocal microscope Olympus
FV1000 as indicated.
4.10. F-actin/G-actin Ratio Determination
Cells (70,000) were seeded in 24-well culture dishes. The cells were cultured in DMEM containing
10% or 1% FBS overnight for cells undergoing non-stimulated or stimulated conditions, respectively.
The next day, the 1% FBS-DMEM was replaced with normal 10% FBS-DMEM for 3 h to stimulate
the cells. This was followed by fixation of the cells in 4% paraformaldehyde for 15 min at room
temperature, permeabilization in 0.5% Triton X-100 for 5 min, and PBS rinsing. An incubation solution
of 2 drops/mL ActinRed 555 (Life Technologies) to stain F-actin and 10 µg/mL Alexa Fluor 488-labeled
DNAseI (Life Technologies) to stain monomeric G-actin was added to the cells for 1 h. After three
washing steps with PBS, images of the F-/G-actin expression were obtained using an Olympus FSX100
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inverted microscope at 5×magnification. The relative ratio of F-/G-actin fluorescence intensity was
determined using ImageJ.
4.11. Parachute Assay
Cells at 70–90% confluency were prelabeled in DMEM containing 10 µg/mL DiI (C18) (a red
fluorescent long-chain dialkylcarbocyanine tracer dye), 5 µg/mL calcein AM (a green fluorescent probe
that can pass through gap junctions), and 2.5 mM probenecid or 10 µM verapamil (an anion transport
inhibitor that minimizes calcein leakage from cells). After 30-min incubation at 37 ◦C, the cells were
trypsinized and sparsely seeded (1:25 to 1:50) into wells containing 50–70% confluent unlabelled cells.
After 4 h of co-culture, all cells were trypsinized, and cell fluorescence was measured by flow cytometry.
The transfer of calcein AM from the prelabeled cells to recipient cells via gap junctions can be detected,
whereas the red fluorescent DiI remains in the donor cell.
4.12. Statistical Analysis
All statistical analyses were performed with GraphPad Prism version 8. Data were tested for
normality using the Shapiro–Wilk test. Comparisons of two groups of parametric data were performed
with Student’s t-test, whereas multiple groups were analyzed by one-way ANOVA using Tukey’s
post-hoc test. Statistical significance was set at p < 0.05. All data are displayed as mean ± SEM.
5. Conclusions
Previous work demonstrated the presence of Cx43 in TNTs and that it potentially regulated the
passage of small molecules between cells through gap junctions. However, TNTs are generally thought
to transfer much larger proteins and organelles, which would not be compatible with the small size
limit of gap junctions of around 1.2 kDa. This work identified Cx43 as a direct regulator of TNT
formation. We also established several key pathways linked to Cx43, including p38, PKA signaling,
ROCK signaling, and FAK signaling, which regulate TNTs in a Cx43-dependent manner. Elucidation
of the role of Cx43 in TNTs brings conceptual advances linking Cx43 to pro-tumorigenicity. A better
understanding of TNT formation could provide a novel avenue for cancer targeting.
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